AR030707A1 - 9-ALFA-CLORO-6-ALFA-FLUOR-17-ALFA-HIDROXI-16-METIL-17-BETA-METOXICARBONIL-ANDROST-1,4-DIENOS, UN PROCESO PARA SU PREPARACIoN , COMPOSICION FARMACEUTICA, Y EL USO DEL MISMO PARA LA FABRICACION DE MEDICAMENTO - Google Patents
9-ALFA-CLORO-6-ALFA-FLUOR-17-ALFA-HIDROXI-16-METIL-17-BETA-METOXICARBONIL-ANDROST-1,4-DIENOS, UN PROCESO PARA SU PREPARACIoN , COMPOSICION FARMACEUTICA, Y EL USO DEL MISMO PARA LA FABRICACION DE MEDICAMENTOInfo
- Publication number
- AR030707A1 AR030707A1 ARP010103032A ARP010103032A AR030707A1 AR 030707 A1 AR030707 A1 AR 030707A1 AR P010103032 A ARP010103032 A AR P010103032A AR P010103032 A ARP010103032 A AR P010103032A AR 030707 A1 AR030707 A1 AR 030707A1
- Authority
- AR
- Argentina
- Prior art keywords
- alfa
- androst
- fluor
- beta
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C07J71/0015—Oxiranes at position 9(11)
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
9.Alfa.-cloro-6-.alfa.-fluor-17.alfa.-hidroxi-16-metil-17-beta-metoxicarbonil-androst-1,4-dienos que comprende un compuesto de la formula (1) en donde R es un grupo orgánico cíclico, monovalente que tiene de 3 a 15 átomos en el sistema del anillo, un proceso para su preparacion, composicion farmacéutica, y el uso del mismo para la fabricacion de un medicamento antiinflamatorio.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0015876.6A GB0015876D0 (en) | 2000-06-28 | 2000-06-28 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR030707A1 true AR030707A1 (es) | 2003-09-03 |
Family
ID=9894607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010103032A AR030707A1 (es) | 2000-06-28 | 2001-06-26 | 9-ALFA-CLORO-6-ALFA-FLUOR-17-ALFA-HIDROXI-16-METIL-17-BETA-METOXICARBONIL-ANDROST-1,4-DIENOS, UN PROCESO PARA SU PREPARACIoN , COMPOSICION FARMACEUTICA, Y EL USO DEL MISMO PARA LA FABRICACION DE MEDICAMENTO |
Country Status (30)
Country | Link |
---|---|
US (1) | US6921757B2 (es) |
EP (1) | EP1299409B1 (es) |
JP (1) | JP4065399B2 (es) |
KR (1) | KR100483865B1 (es) |
CN (1) | CN1214038C (es) |
AR (1) | AR030707A1 (es) |
AT (1) | ATE292639T1 (es) |
AU (2) | AU2001283891B2 (es) |
BR (1) | BR0112068A (es) |
CA (1) | CA2412541C (es) |
CZ (1) | CZ302513B6 (es) |
DE (1) | DE60109931T2 (es) |
EC (1) | ECSP014101A (es) |
ES (1) | ES2240499T3 (es) |
GB (1) | GB0015876D0 (es) |
HK (1) | HK1055974A1 (es) |
HU (1) | HUP0300783A3 (es) |
IL (2) | IL153703A0 (es) |
MX (1) | MXPA02012830A (es) |
MY (1) | MY129523A (es) |
NO (1) | NO324055B1 (es) |
NZ (1) | NZ523194A (es) |
PE (1) | PE20020179A1 (es) |
PL (1) | PL207722B1 (es) |
PT (1) | PT1299409E (es) |
RU (1) | RU2277100C2 (es) |
SK (1) | SK286690B6 (es) |
TW (1) | TWI232868B (es) |
WO (1) | WO2002000679A2 (es) |
ZA (1) | ZA200300202B (es) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
WO2002012265A1 (en) * | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
SI1383786T1 (sl) | 2001-04-30 | 2009-02-28 | Glaxo Group Ltd | Protivnetni 17.beta-karbotioatestrski derivati androstana s ciklično estrsko skupino na položaju 17.alfa |
ES2307751T3 (es) * | 2001-06-12 | 2008-12-01 | Glaxo Group Limited | Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano. |
GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
WO2003042229A1 (en) * | 2001-11-12 | 2003-05-22 | Glaxo Group Limited | Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids |
GB0127160D0 (en) * | 2001-11-12 | 2002-01-02 | Glaxo Group Ltd | Novel compounds |
AU2002356759A1 (en) * | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
WO2003072592A1 (en) * | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
WO2003062259A2 (en) * | 2002-01-21 | 2003-07-31 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
GB0202216D0 (en) * | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
JP2005522442A (ja) * | 2002-02-04 | 2005-07-28 | グラクソ グループ リミテッド | 非晶質フルチカゾン2−フロエート、その医薬組成物およびその結晶非溶媒和形態への変換 |
GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
GB2389530B (en) * | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
GB0217504D0 (en) * | 2002-07-29 | 2002-09-04 | Novartis Ag | Organic compounds |
EP1592422A2 (en) * | 2003-02-11 | 2005-11-09 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
US7507745B2 (en) | 2004-02-20 | 2009-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
JP5138362B2 (ja) | 2004-03-23 | 2013-02-06 | ノバルティス アーゲー | 医薬組成物 |
GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
DE102004025985A1 (de) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estriol- und Estetrol-Prodrugs |
DE102004025966A1 (de) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estradiol-Prodrugs |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
KR20080036632A (ko) | 2005-08-08 | 2008-04-28 | 아젠터 디스커버리 리미티드 | 바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도 |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
CA2625664C (en) | 2005-10-21 | 2016-01-05 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
GB0523654D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0523656D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
GB0603783D0 (en) * | 2006-02-24 | 2006-04-05 | Novartis Ag | Organic compounds |
PT2322525E (pt) | 2006-04-21 | 2013-12-26 | Novartis Ag | Derivados de purina para utilização como agonistas do recetor de adenosina a2a |
CN101553493B (zh) | 2006-07-19 | 2012-07-04 | 阿斯利康(瑞典)有限公司 | 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途 |
GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
CA2664378A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as pi3k lipid kinase inhibitors |
TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
CA2672446A1 (en) | 2006-12-19 | 2008-06-26 | Astrazeneca Ab | Quinuclidinol derivatives as muscarinic receptor antagonists |
AU2007342223B2 (en) | 2007-01-10 | 2011-02-24 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
EP2117541A1 (en) | 2007-02-09 | 2009-11-18 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
ES2361595T3 (es) | 2007-05-07 | 2011-06-20 | Novartis Ag | Compuestos orgánicos. |
MX2010006421A (es) | 2007-12-10 | 2010-06-25 | Novartis Ag | Compuestos organicos. |
AU2009203693B2 (en) | 2008-01-11 | 2012-06-07 | Novartis Ag | Pyrimidines as kinase inhibitors |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
CA2723981A1 (en) | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | New compounds 273 |
CA2721065C (en) | 2008-05-27 | 2016-09-27 | Astrazeneca Ab | Phenoxypyridinylamide derivatives and their use as pde4 inhibitors |
EP2300010B1 (en) | 2008-06-10 | 2015-03-04 | Novartis AG | Pyrazine derivatives as epithelial sodium channel blockers |
WO2010067102A1 (en) | 2008-12-09 | 2010-06-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders |
EA019441B1 (ru) | 2008-12-30 | 2014-03-31 | Палмаджен Терепьютикс (Инфлеммейшн) Лимитед | Сульфонамиды, предназначенные для лечения респираторных нарушений |
TW201031406A (en) | 2009-01-29 | 2010-09-01 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
CN102448978A (zh) * | 2009-05-29 | 2012-05-09 | 辉瑞有限公司 | 新颖的糖皮质激素受体激动剂 |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
CA2770873A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
IN2012DN01961A (es) | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
EP2467383A1 (en) | 2009-08-20 | 2012-06-27 | Novartis AG | Heterocyclic oxime compounds |
WO2011050325A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン, エルエルシー | 複素環化合物およびその使用 |
SG192795A1 (en) | 2011-02-25 | 2013-09-30 | Irm Llc | Compounds and compositions as trk inhibitors |
UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
ES2691650T3 (es) | 2011-09-15 | 2018-11-28 | Novartis Ag | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
ES2558457T3 (es) | 2011-09-16 | 2016-02-04 | Novartis Ag | Compuestos heterocíclicos para el tratamiento de fibrosis quística |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
RU2660354C2 (ru) | 2012-04-03 | 2018-07-05 | Новартис Аг | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2014198909A1 (en) | 2013-06-14 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Rac1 inhibitors for inducing bronchodilation |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
PT3134396T (pt) | 2014-04-24 | 2019-12-16 | Novartis Ag | Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase |
PL3134395T3 (pl) | 2014-04-24 | 2018-07-31 | Novartis Ag | Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu |
KR20160141855A (ko) | 2014-04-24 | 2016-12-09 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피라진 유도체 |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
CN107207510B (zh) | 2014-07-31 | 2019-11-29 | 诺华股份有限公司 | 联合疗法 |
EP3703065A1 (en) | 2015-01-20 | 2020-09-02 | Novartis AG | Application unlock using a connected physical device and transfer of data therebetween |
EP3111978B1 (en) | 2015-07-03 | 2021-09-01 | Novartis AG | Inhaler adapted to read information stored in a data storage means of a container |
CN108129537B (zh) * | 2017-12-19 | 2022-03-01 | 广州健康元呼吸药物工程技术有限公司 | 一种糖皮质激素异构体及其制备方法和用途 |
CN113891744A (zh) | 2019-06-10 | 2022-01-04 | 诺华股份有限公司 | 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物 |
KR20220052934A (ko) | 2019-08-28 | 2022-04-28 | 노파르티스 아게 | 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639434A (en) * | 1967-02-02 | 1972-02-01 | Boots Pure Drug Co Ltd | 17-acyloxysteroids and their manufacture |
US3528080A (en) * | 1968-04-01 | 1970-09-08 | Gen Motors Corp | Carburetor flow test method |
GB1384372A (en) * | 1971-01-20 | 1975-02-19 | Glaxo Lab Ltd | Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids |
US3828080A (en) * | 1972-01-20 | 1974-08-06 | Glaxo Lab Ltd | Androstane-17beta-carboxylic acids and processes for the preparation thereof |
GB1438940A (en) * | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
NL7502252A (nl) * | 1974-02-27 | 1975-08-29 | Pierrel Spa | Werkwijze voor het bereiden van een geneesmid- del met anti-inflammatoire werking, gevormd ge- neesmiddel verkregen volgens deze werkwijze alsmede werkwijze voor het bereiden van in het geneesmiddel gebruikte nieuwe steroiden. |
CH628355A5 (de) * | 1976-02-24 | 1982-02-26 | Ciba Geigy Ag | Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze. |
DE3260474D1 (en) * | 1981-02-02 | 1984-09-06 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
US4607028A (en) | 1983-08-18 | 1986-08-19 | Ciba-Geigy Corporation | Novel carboxylic acid esters |
PE44995A1 (es) | 1994-01-27 | 1995-12-18 | Schering Corp | Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias |
JPH08291072A (ja) | 1995-04-22 | 1996-11-05 | Kissei Pharmaceut Co Ltd | 吸入用粉末製剤用結晶とその製造方法 |
JPH08291073A (ja) * | 1995-04-22 | 1996-11-05 | Kissei Pharmaceut Co Ltd | 医薬品組成物及びその製造方法 |
-
2000
- 2000-06-28 GB GBGB0015876.6A patent/GB0015876D0/en not_active Ceased
-
2001
- 2001-06-20 EC EC2001004101A patent/ECSP014101A/es unknown
- 2001-06-26 PE PE2001000620A patent/PE20020179A1/es not_active Application Discontinuation
- 2001-06-26 CA CA002412541A patent/CA2412541C/en not_active Expired - Fee Related
- 2001-06-26 CN CNB018117430A patent/CN1214038C/zh not_active Expired - Fee Related
- 2001-06-26 TW TW090115444A patent/TWI232868B/zh not_active IP Right Cessation
- 2001-06-26 DE DE60109931T patent/DE60109931T2/de not_active Expired - Lifetime
- 2001-06-26 MY MYPI20013015A patent/MY129523A/en unknown
- 2001-06-26 PT PT01962783T patent/PT1299409E/pt unknown
- 2001-06-26 KR KR10-2002-7017949A patent/KR100483865B1/ko not_active IP Right Cessation
- 2001-06-26 PL PL358428A patent/PL207722B1/pl not_active IP Right Cessation
- 2001-06-26 NZ NZ523194A patent/NZ523194A/en not_active IP Right Cessation
- 2001-06-26 US US10/312,021 patent/US6921757B2/en not_active Expired - Fee Related
- 2001-06-26 ES ES01962783T patent/ES2240499T3/es not_active Expired - Lifetime
- 2001-06-26 JP JP2002505801A patent/JP4065399B2/ja not_active Expired - Fee Related
- 2001-06-26 AT AT01962783T patent/ATE292639T1/de active
- 2001-06-26 AU AU2001283891A patent/AU2001283891B2/en not_active Ceased
- 2001-06-26 AU AU8389101A patent/AU8389101A/xx active Pending
- 2001-06-26 RU RU2003100504/04A patent/RU2277100C2/ru not_active IP Right Cessation
- 2001-06-26 HU HU0300783A patent/HUP0300783A3/hu unknown
- 2001-06-26 MX MXPA02012830A patent/MXPA02012830A/es active IP Right Grant
- 2001-06-26 EP EP01962783A patent/EP1299409B1/en not_active Expired - Lifetime
- 2001-06-26 IL IL15370301A patent/IL153703A0/xx active IP Right Grant
- 2001-06-26 CZ CZ20024203A patent/CZ302513B6/cs not_active IP Right Cessation
- 2001-06-26 AR ARP010103032A patent/AR030707A1/es active IP Right Grant
- 2001-06-26 SK SK1813-2002A patent/SK286690B6/sk not_active IP Right Cessation
- 2001-06-26 BR BR0112068-9A patent/BR0112068A/pt not_active IP Right Cessation
- 2001-06-26 WO PCT/EP2001/007249 patent/WO2002000679A2/en active IP Right Grant
-
2002
- 2002-12-26 IL IL153703A patent/IL153703A/en not_active IP Right Cessation
- 2002-12-27 NO NO20026253A patent/NO324055B1/no not_active IP Right Cessation
-
2003
- 2003-01-08 ZA ZA200300202A patent/ZA200300202B/xx unknown
- 2003-10-22 HK HK03107633A patent/HK1055974A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR030707A1 (es) | 9-ALFA-CLORO-6-ALFA-FLUOR-17-ALFA-HIDROXI-16-METIL-17-BETA-METOXICARBONIL-ANDROST-1,4-DIENOS, UN PROCESO PARA SU PREPARACIoN , COMPOSICION FARMACEUTICA, Y EL USO DEL MISMO PARA LA FABRICACION DE MEDICAMENTO | |
AR027060A1 (es) | Bases de mannich de 1-naftol y 2-naftol sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos, asi como el uso deestos compuestos para la fabricacion de medicamentos | |
AR025959A1 (es) | DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
AR022008A1 (es) | Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento | |
AR063555A1 (es) | Derivados de androstano, su uso en la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden y procesos para prepararlos | |
AR025052A1 (es) | Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos. | |
ES2065701T3 (es) | Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas. | |
AR029463A1 (es) | Pirrolidinas disustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
AR066982A2 (es) | Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos | |
AR005053A1 (es) | Compuestos de difenilhexano, un procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos, y procedmientos para la manufactura de medicamentos para inhibir la infeccion de hiv | |
SV1999000048A (es) | Uso de dihidropiriminas como medicamento y nuevas sustancias ref. lea 32 791-sv | |
DK0421561T3 (da) | 24-homo-vitamin-D-derivater, fremgangsmåder til fremstilling heraf, farmaceutiske præparater indeholdende disse derivater samt deres anvendelse som lægemiddel | |
AR029509A1 (es) | Una composicion farmaceutica en base a un compuesto de platino (iv) y el uso de dicho compuesto para preparar medicamentos antitumorales | |
BR0107899A (pt) | Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida | |
AR022588A1 (es) | Derivados de mevinolina | |
UY28909A1 (es) | Prodrogas de estradiol | |
AR029795A1 (es) | Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos | |
UY28910A1 (es) | Prodrogas de estriol y estetrol | |
AR030662A1 (es) | Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos | |
ES2102043T3 (es) | Derivados de 22-en-25-oxa en la serie de la vitamina d, procedimiento para su preparacion, preparados farmaceuticos que los contienen, asi como su utilizacion en calidad de medicamentos. | |
ES2192853T3 (es) | Compuestos ciclicos utiles en el tratamiento de la dislipidemia, aterosclerosis y diabetes, composiciones farmaceuticas y proceso de preparacion. | |
AR044869A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion | |
ES2032582T3 (es) | Procedimiento para preparar derivados de la oxima del 1,2,5,6,-tetrahidropiridin -3-carboxialdehido. | |
AR003434A1 (es) | Compuesto de tiludronato, composiciones farmaceuticas que los contienen y proceso para producir dicho compuesto y procedimiento para producir lascomposiciones farmaceuticas. | |
HN2001000002A (es) | PIRAZOLO [4,3-e] DIAZEPINAS SUSTITUIDAS NOVEDOSAS, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN, SU USO COMO PRODUCTOS MEDICINALES Y PROCESOS PARA PREPARARLAS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |